This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Blue-Chip Stock Buys to Beat the S&P

Laboratory Corporation of America

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Up first on our list of most hated stocks is Laboratory Corporation of America (LH - Get Report) -- LabCorp for short. This $9 billion firm is one of the largest independent medical lab operators in the U.S., with more than 1,700 patient service centers that provide everything from run-of-the-mill blood tests to more specialized genetic and oncology testing.

But investors hate this stock right now; short sellers have ratcheted LH's short interest ratio up to 13.7, which means that it would take the better part of three weeks for shorts to buy enough shares of LabCorp to cover their bets.

>>5 Rocket Stocks to Buy in October

LabCorp owns around 20% of the independent laboratory market, giving it scale in a business where size certainly matters. Let's face it, medical testing isn't exactly the most exciting business out there, and as a result, patients don't care where they get their medical tests done. As long as the lab is covered by their insurance, location is the deciding factor. So, with a network that spans a bigger geographic footprint, LabCorp's patient net is bigger.

Scale is also important in working out deals with medical providers on one side and insurers on the other. Because LH cuts a big swath, it can make more important deals with both groups.

The introduction of more complex testing products is a big deal for LabCorp - it opens the firm up to testing that yields much higher margins than the run-of-the-mill blood work can provide. As physicians opt for a fuller picture of a patient's health, LH should be able to keep pushing its net margins into the double digits.

Earnings next week are still a big question mark, but for risk-hungry investors, the earnings call could be the big catalyst for shorts to start buying back shares.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
SIAL $139.76 -0.04%
GPC $86.22 0.00%
LH $104.59 0.00%
SYY $42.71 0.00%
UAL $47.71 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs